• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
EPZM

EPZM

Epizyme, Inc.

NASDAQHealthcareBiotechnologyUS

USD1.47

+0.00 (+0.00%)

Company Profile

CEO

Robert Bazemore

IPO Date

2013-05-31

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$1.49

Prev. Close

$1.47

Day Low

$1.47

Day High

$1.50

52W Low

$0.41

52W High

$5.80

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentNeutral

Articles

10

Avg Positive

28.0%

Avg Negative

30.0%

Avg Neutral

42.0%

News Feed

Epizyme's (EPZM) Q2 Earnings Miss, Revenues Beat Estimates

Zacks Investment Research·8/10/2021·↓ negative

Why Epizyme Is Getting Crushed Today

The Motley Fool·8/9/2021·↓ negative

Epizyme, Inc. (EPZM) CEO Rob Bazemore on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/9/2021·↓ negative

Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research·8/9/2021·↑ positive

Epizyme Announces CEO Succession

Business Wire·8/9/2021·↑ positive

Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update

Business Wire·8/9/2021·↑ positive

Epizyme and HUTCHMED Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

Business Wire·8/8/2021·↑ positive

Why Epizyme Stock Is Falling This Week

The Motley Fool·7/2/2021·↓ negative

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Seeking Alpha·6/22/2021·↑ positive

Epizyme's Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models

Benzinga·6/14/2021·↓ negative